Skip to main navigation
Skip to search
Skip to main content
Sort by
Medicine and Dentistry
Chemoradiotherapy
100%
Hypopharyngeal Cancer
93%
Pembrolizumab
93%
Non Small Cell Lung Cancer
84%
Disease
82%
Overall Survival
57%
Malignant Neoplasm
56%
Biological Marker
53%
Therapy Delay
53%
Radioimmunotherapy
46%
Lung Cancer Screening
46%
Human Immunodeficiency Virus
46%
Odds Ratio
46%
Urban Population
46%
Cancer Therapy
46%
Survival Analysis
46%
Predictive Factor
46%
Cohort Effect
46%
Lung Cancer
46%
Abdominal Cancer
46%
Meningeal Carcinomatosis
46%
Squamous Cell
46%
Neck
46%
Cancer Cell
46%
Recurrent Disease
46%
Placebo
46%
Hazard Ratio
46%
Programmed Death-Ligand 1
43%
Progression Free Survival
40%
Neoplasm
37%
Diseases
35%
Disease Specific Survival
33%
Radiation Therapy
33%
Breast Cancer
28%
Colorectal Cancer
28%
Head and Neck Cancer
28%
Adverse Event
27%
Cancer
26%
Immunotherapy
26%
Tumor Mutation Burden
23%
Dabrafenib
23%
Proportional Hazards Model
19%
Head and Neck Squamous Cell Carcinoma
19%
Care Coordination
18%
Pancreas Cancer
18%
Charlson Comorbidity Index
18%
Cytotechnology
18%
Lumbar Puncture
18%
Methotrexate
18%
Systemic Therapy
18%
Keyphrases
Advanced Hypopharyngeal Cancer
93%
Chemoradiation
46%
Sinonasal Malignancy
46%
National Cancer Database
46%
POLE mutation
46%
Primary Surgery
46%
Survival Analysis
46%
Cancer Treatment Delay
46%
Randomized Double-blind
46%
Placebo-controlled
46%
Placebo
46%
Phase II Study
46%
Squamous Cell Cancer
46%
Head-and-neck
46%
Pembrolizumab
46%
High Risk
46%
Progression-free Survival
36%
Overall Survival
28%
Hazard Ratio
25%
Head-and-neck Squamous Cell Carcinoma (HNSCC)
25%
Propensity Score
23%
Improved Survival
23%
Primary Chemoradiation
23%
Exonuclease Domain
23%
Cox Regression Analysis
23%
Long-term Survival
23%
BRAF K601E mutation
23%
SMARCB1-deficient Sinonasal Carcinoma
15%
Anti-PD-1 Therapy
15%
Kaplan-Meier Analysis
11%
Facility Type
11%
N Stage
11%
Adult Patients
11%
Propensity Score Adjustment
11%
American College of Surgeons
11%
Histology
11%
T Stage
11%
Adjuvant Chemoradiation
11%
Treatment Group
11%
Sensitivity Analysis
11%
Insurance Status
11%
Treatment Survival
11%
Facility Location
11%
Multiple Facilities
11%
Locoregionally Advanced
11%
Treatment Delay
11%
Median Survival
11%
T4 Disease
11%
Hypopharyngeal Squamous Cell Carcinoma
11%
Adjuvant Radiation
11%
Pharmacology, Toxicology and Pharmaceutical Science
Pembrolizumab
93%
Thyroid Papillary Carcinoma
46%
Mitogenic Agent
46%
Hypopharynx Cancer
46%
Thyroid Cancer
46%
Non Small Cell Lung Cancer
46%
Phosphotransferase Inhibitor
46%
Squamous Cell Carcinoma
46%
Recurrent Disease
46%
Placebo
46%
Progression Free Survival
40%
Adverse Event
34%
Neoplasm
33%
Disease
29%
Recurrence Risk
27%
Thyroid Carcinoma
23%
Poorly Differentiated Thyroid Cancer
23%
Dabrafenib
23%
Trametinib
23%
Mitogen Activated Protein Kinase
23%
Head and Neck Squamous Cell Carcinoma
19%
Overall Survival
17%
Survival Rate
17%
Chemotherapy
13%
Diseases
7%
Chemoradiation Therapy
6%
Biological Marker
6%
Disease Exacerbation
6%
Durvalumab
6%
Colitis
6%
Esophagitis
6%